ALLIANCE PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.9 GBX | -3.42% |
|
-12.63% | -16.30% |
| May. 30 | Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies | CI |
| May. 21 | Alliance Pharma plc Announces the Appointment of Nicholas John Sedgwick as Director | CI |
| Sales 2023 * | 183M 233M | Sales 2024 * | 196M 250M | Capitalization | 183M 233M |
|---|---|---|---|---|---|
| Net income 2023 * | 17M 21.63M | Net income 2024 * | 18M 22.9M | EV / Sales 2023 * | 1.5 x |
| Net Debt 2023 * | 92.2M 117M | Net Debt 2024 * | 69.1M 87.92M | EV / Sales 2024 * | 1.29 x |
| P/E ratio 2023 * |
10.3
x | P/E ratio 2024 * |
10.3
x | Employees | 285 |
| Yield 2023 * |
2.99% | Yield 2024 * |
3.05% | Free-Float | 88.24% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.42% | ||
| 1 week | -12.63% | ||
| Current month | -12.63% | ||
| 1 month | +7.28% | ||
| 3 months | -14.72% | ||
| 6 months | -12.52% | ||
| Current year | -16.30% |
1 week
33.76
39.95
1 month
32.8541.70
Current year
24.5546.00
1 year
24.5560.50
3 years
24.55123.00
5 years
24.55123.00
10 years
24.55123.00
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Franklin
DFI | Director of Finance/CFO | 58 | 15-09-27 |
Jeyan Heper
COO | Chief Operating Officer | - | 23-01-31 |
| Chief Tech/Sci/R&D Officer | 56 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 49 | 10-02-21 | |
| Director/Board Member | 55 | 23-01-31 | |
Richard Jones
BRD | Director/Board Member | 58 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 33.9 | -3.42% | 7,738,743 |
| 24-06-06 | 35.1 | -4.62% | 1,072,671 |
| 24-06-05 | 36.8 | -2.00% | 887,573 |
| 24-06-04 | 37.55 | -3.72% | 763,733 |
| 24-06-03 | 39 | +0.52% | 2,654,623 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotes
Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.
Sector
Pharmaceuticals
Calendar
2024-09-23
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.339
GBP
Average target price
0.6529
GBP
Spread / Average Target
+92.58%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.30% | 233M | |
| +19.64% | 43.3B | |
| +23.27% | 22.22B | |
| +18.92% | 15.43B | |
| +20.14% | 14.48B | |
| +53.19% | 12.72B | |
| -0.05% | 6.79B | |
| -10.87% | 6.71B | |
| -8.87% | 5.73B | |
| +14.68% | 5.5B |
- Stock Market
- Equities
- APH Stock
